Publications by authors named "M Jeppesen"

Claim this Profile
E
Elexacaftor/tezacaftor/ivacaftor corrects salt-wasting in cystic fibrosis.
Peder Berg, Amalie Quist Rousing, Søren Jensen-Fangel, Sascha Bandulik, Richard Warth, Majbritt Jeppesen

J Cyst Fibros· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes of nontuberculous mycobacterial infection in the Danish Cystic Fibrosis Cohort 2012-23.
Christian Leo-Hansen, Bibi U Nielsen, Thomas Bryrup, Majbritt Jeppesen, Mette Kolpen

J Cyst Fibros· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding vulnerability and diabetes management in families of children with type 1-diabetes - A qualitative study.
Marie Nedergaard Jeppesen, Jane Clemensen, Malene Søborg Heidemann, Birgitte Hertz, Bodil Rasmussen

J Pediatr Nurs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis.
Karlen Bader-Larsen, Bibi Uhre Nielsen, Esben Henriksen, Thomas Bryrup, Christian Leo-Hansen, Majbritt Jeppesen

Clin Nutr· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort.
Christine Højte, Mette Frahm Olsen, Daniel Faurholt-Jepsen, Marianne Hørby Jørgensen, Tacjana Pressler, Majbritt Jeppesen

J Cyst Fibros· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis